RU2005136383A - Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов - Google Patents
Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов Download PDFInfo
- Publication number
- RU2005136383A RU2005136383A RU2005136383/14A RU2005136383A RU2005136383A RU 2005136383 A RU2005136383 A RU 2005136383A RU 2005136383/14 A RU2005136383/14 A RU 2005136383/14A RU 2005136383 A RU2005136383 A RU 2005136383A RU 2005136383 A RU2005136383 A RU 2005136383A
- Authority
- RU
- Russia
- Prior art keywords
- thrombin
- active ingredient
- agent
- increased
- pharmaceutical composition
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims 11
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title claims 4
- 229960002768 dipyridamole Drugs 0.000 title claims 4
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 title claims 4
- 229950010718 mopidamol Drugs 0.000 title claims 4
- 230000009424 thromboembolic effect Effects 0.000 title claims 4
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000002829 reductive effect Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 108090000190 Thrombin Proteins 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 229960004072 thrombin Drugs 0.000 claims 15
- 102000003790 Thrombin receptors Human genes 0.000 claims 13
- 108090000166 Thrombin receptors Proteins 0.000 claims 13
- 239000004480 active ingredient Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000003524 antilipemic agent Substances 0.000 claims 5
- 239000005541 ACE inhibitor Substances 0.000 claims 4
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 206010047249 Venous thrombosis Diseases 0.000 claims 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 239000003472 antidiabetic agent Substances 0.000 claims 4
- 229940125708 antidiabetic agent Drugs 0.000 claims 4
- 230000003143 atherosclerotic effect Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 206010003178 Arterial thrombosis Diseases 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 208000005189 Embolism Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229960004676 antithrombotic agent Drugs 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000003073 embolic effect Effects 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229960001929 meloxicam Drugs 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 229940019331 other antithrombotic agent in atc Drugs 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Chemical group 0.000 claims 2
- 229960000371 rofecoxib Drugs 0.000 claims 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000007214 atherothrombosis Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical group N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims 1
- 229960000288 dabigatran etexilate Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
- 229960005080 warfarin Drugs 0.000 claims 1
- 229960001522 ximelagatran Drugs 0.000 claims 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46516803P | 2003-04-24 | 2003-04-24 | |
| US60/465,168 | 2003-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005136383A true RU2005136383A (ru) | 2007-06-10 |
Family
ID=33311001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005136383/14A RU2005136383A (ru) | 2003-04-24 | 2004-04-17 | Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов |
Country Status (12)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2377990C1 (ru) * | 2008-07-23 | 2010-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов |
| RU2530645C2 (ru) * | 2008-11-11 | 2014-10-10 | Берингер Ингельхайм Интернациональ Гмбх | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| US7064130B2 (en) * | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| AU2005245271A1 (en) | 2004-05-13 | 2005-12-01 | Boehringer Ingelheim International Gmbh | Use of dipyridamole for treatment of resistance to platelet inhibitors |
| JP2008517974A (ja) * | 2004-10-25 | 2008-05-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用 |
| US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
| DE102005028168B3 (de) | 2005-06-17 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Einrichtung zur Führung eines Gases für Vorrichtungen zum Behandeln körnigen Gutes durch Trocknen, Filmcoaten oder Beschichten, insbesondere Zulufteinheit und Vorrichtung mit einer derartigen Einrichtung |
| CA2657269A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New indications for direct thrombin inhibitors |
| CA2657270A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New paediatric indications for direct thrombin inhibitors |
| JP2009543842A (ja) * | 2006-07-17 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓血管分野における直接トロンビン阻害薬のための新規適応 |
| WO2009080301A1 (en) * | 2007-12-21 | 2009-07-02 | Boehringer Ingelheim International Gmbh | Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke |
| JP2012500244A (ja) * | 2008-08-19 | 2012-01-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍療法におけるダビガトラン |
| WO2011085473A1 (en) * | 2010-01-13 | 2011-07-21 | Linda Penn | Treating cancer with statins and compounds having dipyridamole activity |
| AU2016337564A1 (en) * | 2015-10-15 | 2018-05-31 | Drug Rediscovery Group Ltd | Low dose oral dipyridamole compositions and uses thereof |
| US12606797B2 (en) * | 2018-06-15 | 2026-04-21 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of detection of mechanically-activated platelet activation and uses thereof |
| US20260060965A1 (en) * | 2024-08-26 | 2026-03-05 | Research Institute at Nationwide Children’s Hospital | Modulating the acute foreign body reaction to reduce stenosis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3031450A (en) | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
| GB1051218A (cg-RX-API-DMAC10.html) | 1963-03-09 | |||
| DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3237575A1 (de) | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
| DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| DE4035961A1 (de) | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| US6979462B1 (en) * | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
| US20020048599A1 (en) | 2000-10-20 | 2002-04-25 | Thomas H. Mueller | Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation |
| HUP0304058A2 (hu) * | 2001-01-30 | 2004-04-28 | Bristol-Myers Squibb Company | Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| EP1250921A1 (en) | 2001-04-21 | 2002-10-23 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast disintegrating meloxicam tablet |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
| EP1308179A1 (en) * | 2001-10-30 | 2003-05-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Improved endoprosthetic device |
| US20030180282A1 (en) * | 2002-03-25 | 2003-09-25 | Victor Serebruany | Method of treatment of thrombotic events |
| JP2006500365A (ja) * | 2002-08-14 | 2006-01-05 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | ｐ３８ＭＡＰキナーゼインヒビターを用いた抗凝固及び線維素溶解療法 |
| JP2006516593A (ja) * | 2003-02-07 | 2006-07-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用 |
-
2004
- 2004-04-17 WO PCT/EP2004/004097 patent/WO2004093881A2/en not_active Ceased
- 2004-04-17 RU RU2005136383/14A patent/RU2005136383A/ru not_active Application Discontinuation
- 2004-04-17 BR BRPI0409796-3A patent/BRPI0409796A/pt not_active IP Right Cessation
- 2004-04-17 CA CA002523157A patent/CA2523157A1/en not_active Abandoned
- 2004-04-17 MX MXPA05011432A patent/MXPA05011432A/es not_active Application Discontinuation
- 2004-04-17 JP JP2006505175A patent/JP2006524203A/ja active Pending
- 2004-04-17 EP EP04728114A patent/EP1622621A2/en not_active Withdrawn
- 2004-04-17 AU AU2004231306A patent/AU2004231306A1/en not_active Abandoned
- 2004-04-17 EP EP09152218A patent/EP2062580A1/en not_active Withdrawn
- 2004-04-17 KR KR1020057020187A patent/KR20060007034A/ko not_active Withdrawn
- 2004-04-17 CN CNA200480017862XA patent/CN1812792A/zh active Pending
- 2004-04-22 US US10/830,294 patent/US20050014770A1/en not_active Abandoned
-
2005
- 2005-10-04 ZA ZA200508016A patent/ZA200508016B/en unknown
-
2006
- 2006-09-01 US US11/469,503 patent/US20070105753A1/en not_active Abandoned
-
2009
- 2009-04-03 US US12/418,001 patent/US20090192123A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2377990C1 (ru) * | 2008-07-23 | 2010-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов |
| RU2530645C2 (ru) * | 2008-11-11 | 2014-10-10 | Берингер Ингельхайм Интернациональ Гмбх | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050014770A1 (en) | 2005-01-20 |
| CN1812792A (zh) | 2006-08-02 |
| US20070105753A1 (en) | 2007-05-10 |
| CA2523157A1 (en) | 2004-11-04 |
| MXPA05011432A (es) | 2006-03-21 |
| WO2004093881A3 (en) | 2005-06-16 |
| EP2062580A1 (en) | 2009-05-27 |
| EP1622621A2 (en) | 2006-02-08 |
| BRPI0409796A (pt) | 2006-05-30 |
| KR20060007034A (ko) | 2006-01-23 |
| WO2004093881A2 (en) | 2004-11-04 |
| US20090192123A1 (en) | 2009-07-30 |
| AU2004231306A1 (en) | 2004-11-04 |
| JP2006524203A (ja) | 2006-10-26 |
| ZA200508016B (en) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008195736A (ja) | 医薬組成物 | |
| Power et al. | Analgesic agents for the postoperative period: nonopioids | |
| AU2013334874B2 (en) | Combination therapies for the treatment of Alzheimer's disease and related disorders | |
| JP2012502915A (ja) | てんかんを治療する組成物及び方法 | |
| AU2021231064B2 (en) | Treatment of pain and vasoconstriction | |
| TW201219372A (en) | Compositions and methods of treating pulmonary hypertension | |
| US20110195049A1 (en) | Compositions and methods for treating multiple sclerosis | |
| US20090247582A1 (en) | Methods of treating atherosclerosis | |
| JP2006524203A5 (cg-RX-API-DMAC10.html) | ||
| WO2005117872A2 (en) | Dual acting snri-nmda antagonists for the treatment of genitourinary disorders | |
| CN1812792A (zh) | 双嘧达莫或单哌潘生丁用于治疗和预防凝血酶过量产生和/或凝血酶受体表达增加引起的血栓栓塞疾病和紊乱 | |
| US8618148B2 (en) | Use of telmisartan for the prevention and treatment of vascular headache | |
| WO2001005428A1 (en) | Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof | |
| WO2010006103A1 (en) | Method for enhancing cognition or inhibiting cognitive decline | |
| JP2006096665A (ja) | 脊柱管狭窄症治療剤 | |
| KR20060123183A (ko) | 탈리도미드를 포함하는 섬유근육통 치료용 조성물 및 그방법 | |
| KR20060130619A (ko) | 유기 화합물의 조합물 | |
| RU2007115092A (ru) | Аминоспиртовые производные | |
| JP2006527244A (ja) | アルツハイマー病及び関連状態の治療 | |
| Vet—QB01AA04 | 1370 Cardiovascular Drugs | |
| WO2006115302A1 (ja) | 神経因性疼痛治療剤 | |
| WO1999007403A1 (fr) | Medicaments nootropes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20081205 |